LENZ Therapeutics to Present at Upcoming Investor Conferences
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference Date: December 2, 2025Location: New York City, NYFormat: Fireside chat at 3:30pm ET (live audio webcast) and 1x1 investor meetings 8th Annual Evercore Healthcare ConferenceDate: December 3, 2025Location: Coral Gables, FLFormat: Fireside chat at 1:20pm ET (live audio webcast) and 1x1 investor meetings Citi’s 2025 Global Healthcare ConferenceDate: December 4, 2025Location: Miami, FLFormat: Fireside chat at 10:30am ET (live audio webcast) and 1x1 investor meetings Live audio webcasts will also be available on the
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of PresbyopiaGlobeNewswire
- LENZ Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics (NASDAQ:LENZ) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Insider Spends US$239k Buying More Shares In LENZ Therapeutics [Yahoo! Finance]Yahoo! Finance
- Analysts Are Upgrading LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Its Latest Results [Yahoo! Finance]Yahoo! Finance
LENZ
Earnings
- 11/5/25 - Beat
LENZ
Sec Filings
- 11/19/25 - Form 4
- 11/17/25 - Form 144
- 11/14/25 - Form SCHEDULE
- LENZ's page on the SEC website